 |
|
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clin Mol Hepatol. 2025;31(Suppl):S32-S50. Published online 2024 Aug 19 DOI: https://doi.org/10.3350/cmh.2024.0431
|
|
Citations to this article as recorded by
 Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults
Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu
Annals of Hepatology.2025; 30(2): 101583. CrossRef Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease
Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang
Diabetes & Metabolism.2025; 51(1): 101602. CrossRef High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls
Wissal Abassi, Nejmeddine Ouerghi, Mohamed Bessem Hammami, Nidhal Jebabli, Moncef Feki, Anissa Bouassida, Katja Weiss, Beat Knechtle
Nutrients.2025; 17(1): 164. CrossRef Hepatic Estrogen Receptor Alpha Overexpression Protects Against Hepatic Insulin Resistance and MASLD
Ester S. Alves, Jessica D. M. Santos, Alessandra G. Cruz, Felipe N. Camargo, Carlos H. Z. Talarico, Anne R. M. Santos, Carlos A. A. Silva, Henrique J. N. Morgan, Sandro L. Matos, Layanne C. C. Araujo, João Paulo Camporez
Pathophysiology.2025; 32(1): 1. CrossRef Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
Fan Zhang, Longgen Liu, Wenjian Li
Nutrition Journal.2025;[Epub] CrossRef The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014
Ruli Wang, Ningxi Wu, Huan Qu, Xiaowei Zheng, Haoyang Zhang, Lihong Zhu, Xiaolei Wang, Xiaodie Yao, Le Zhang
Frontiers in Endocrinology.2025;[Epub] CrossRef Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort
Xin Zhang, Haili Wang, Chengnan Guo, Shuzhen Zhao, Yi Li, Zhenqiu Liu, Tiejun Zhang
Digestive and Liver Disease.2025;[Epub] CrossRef Tetrahydrocurcumin Alleviates Metabolic Dysfunction-Associated Steatohepatitis in Mice by Regulating Serum Lipids, Bile Acids, and Gut Microbiota
Shang Peng, Moran Meng, Ping Luo, Jiao Liu, Junjun Wang, Yong Chen
International Journal of Molecular Sciences.2025; 26(3): 895. CrossRef Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
Katharina L. Hupa-Breier, Heiko Schenk, Alejandro Campos-Murguia, Freya Wellhöner, Benjamin Heidrich, Janine Dywicki, Björn Hartleben, Clara Böker, Julian Mall, Christoph Terkamp, Ludwig Wilkens, Friedrich Becker, Karl Lenhard Rudolph, Michael Peter Manns
Molecular Metabolism.2025; 93: 102104. CrossRef Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
Cells.2025; 14(3): 221. CrossRef Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
Yunfei Wu, Guojun Zheng, Fan Zhang, Wenjian Li
Frontiers in Immunology.2025;[Epub] CrossRef Liver fibrosis progression analyzed with AI predicts renal decline
Dan-Qin Sun, Jia-Qi Shen, Xiao-Fei Tong, Ya-Yun Ren, Hai-Yang Yuan, Yang-Yang Li, Xin-Lei Wang, Sui-Dan Chen, Pei-Wu Zhu, Xiao-Dong Wang, Christopher D. Byrne, Giovanni Targher, Lai Wei, Vincent W.S. Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming-Hua Zhen
JHEP Reports.2025; 7(5): 101358. CrossRef Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis
Adrian Rotaru, Remus Stafie, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Horia Minea, Laura Huiban, Tudor Cuciureanu, Cristina Muzica, Stefan Chiriac, Irina Girleanu, Ana-Maria Singeap, Catalin Sfarti, Carol Stanciu, Anca Trifan
Life.2025; 15(2): 288. CrossRef Sex differences in diet-induced MASLD – are female mice naturally protected?
Jana Meyer, Ana Mendes Teixeira, Sandy Richter, Dean P. Larner, Asifuddin Syed, Nora Klöting, Madlen Matz-Soja, Susanne Gaul, Anja Barnikol-Oettler, Wieland Kiess, Diana Le Duc, Melanie Penke, Antje Garten
Frontiers in Endocrinology.2025;[Epub] CrossRef Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis
Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nak
Journal of Gastroenterology.2025; 60(7): 891. CrossRef Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef A Narrative Review on the Risk Factors and Healthcare Disparities of Type 2 Diabetes
Elvira Meni Maria Gkrinia, Andrej Belančić
Diabetology.2025; 6(4): 25. CrossRef Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur
Stergios A. Polyzos, Christos S. Mantzoros
Metabolism.2025; 168: 156253. CrossRef Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives
Yilong Chen, Shuixiu Bian, Jiamei Le
Genes.2025; 16(4): 399. CrossRef Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques
Pirangi Srikanth, Khaja Moinuddin Shaik, Vijay Patibandla, Deepak Kumar, Sukhendu Nandi
Exploration of Endocrine and Metabolic Diseases.2025;[Epub] CrossRef Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
Hannah Mohr, Jonathan G. Stine
Alimentary Pharmacology & Therapeutics.2025; 61(9): 1565. CrossRef The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes
Dominika Lorek, Krzysztof Łupina, Wiktoria Bisaga, Dominik Malicki, Weronika Stępień, Laura Kumor, Jakub Janczura
Korean Journal of Family Medicine.2025; 46(2): 61. CrossRef Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho
Trends in Endocrinology & Metabolism.2025;[Epub] CrossRef Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting
Edgar A. Villavicencio, Cindy Serdjebi, Adriana Maldonado, Estefania Ochoa Mora, Adrien Besson, Naim Alkhouri, David O. Garcia
Clinics and Research in Hepatology and Gastroenterology.2025; 49(5): 102581. CrossRef Potential bidirectional communication between the liver and the central circadian clock in MASLD
Frédéric Gachon, Elisabetta Bugianesi, Gabriele Castelnuovo, Henrik Oster, Julie S. Pendergast, Sara Montagnese
npj Metabolic Health and Disease.2025;[Epub] CrossRef Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy
云飞 曲
Journal of Clinical Personalized Medicine.2025; 04(02): 826. CrossRef GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
Clinical and Molecular Hepatology.2025; 31(2): e145. CrossRef Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy
Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan
Frontiers in Nutrition.2025;[Epub] CrossRef The Unequal Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease in 204 Countries and Territories From 1990 to 2021
Junqiao Feng, Yudan Fan
Liver International.2025;[Epub] CrossRef Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs
Nicola Pugliese, Davide Polverini, Stefano Ciardullo
Liver International.2025;[Epub] CrossRef Multi‐Center, Multi‐Vendor Validation of Simultaneous MRI‐Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction‐R2* Phantom
Jitka Starekova, David Rutkowski, Won C. Bae, Hung Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando
Journal of Magnetic Resonance Imaging.2025;[Epub] CrossRef Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease
Murali Krishna Moka, Deepalaxmi Rathakrishnan, D.K. Sriram, Melvin George
Clinical Nutrition.2025; 49: 52. CrossRef Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He
International Journal of Molecular Sciences.2025; 26(9): 4077. CrossRef Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?
Luciana Agoglia, Maria Chiara Chindamo, Cristiane Villela-Nogueira
World Journal of Hepatology.2025;[Epub] CrossRef Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease
Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez
World Journal of Hepatology.2025;[Epub] CrossRef Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus
Chun-Hua Wang, Xuan-Yao Ji, Nian Ji, Qing-Feng Yan, Hong-Qing Xu, Xue-Qin Wang, Xiang-Fan Chen, Chun-Feng Lu
BMC Endocrine Disorders.2025;[Epub] CrossRef Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease
Lissette Duarte, Fabien Magne, Martin Gotteland
Current Opinion in Clinical Nutrition & Metabolic Care.2025; 28(4): 307. CrossRef Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease
Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou
BMC Gastroenterology.2025;[Epub] CrossRef Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies
Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral
Food and Agricultural Immunology.2025;[Epub] CrossRef Association between urinary albumin-to-creatinine ratio and all-cause and cardiovascular-cause mortality among MASLD: NHANES 2001–2018
Zhengjin Wang, Zhangxin Chen, Hanxu Zhuang
Frontiers in Nutrition.2025;[Epub] CrossRef Early burden, enduring risk: The alarming outcomes of pediatric MASLD
Marialena Mouzaki
Hepatology.2025;[Epub] CrossRef Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
Yee Hui Yeo, Yixuan Zhu, Jingli Gao, Shanghao Liu, Wenjing Ni, Fajuan Rui, Xue Bai, Nan Geng, Rui Jin, Elizabeth K. Speliotes, Chao Wu, Junping Shi, Xiaolong Qi, Vincent L. Chen, Philip N. Newsome, Jie Li
Alimentary Pharmacology & Therapeutics.2025; 62(2): 168. CrossRef Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
Journal of Advanced Research.2025;[Epub] CrossRef Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index
Yu Pu, Zongbiao Tan, Yanrui Wu, Suqi Zeng, Haodong He, Jixiang Zhang, Weiguo Dong
Frontiers in Nutrition.2025;[Epub] CrossRef Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018
Xiaodie Wei, Xiaohui Liu, Jinhan Zhao, Yang Zhang, Lixia Qiu, Jing Zhang
Frontiers in Aging.2025;[Epub] CrossRef Low carbohydrate and low-calorie diets reduce liver fat and lower brain glutamate and myo-inositol levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Andreana P. Haley, Jack Knight-Scott, Marie Caillaud, Isabelle Gallagher, Jessica Park, Yanrong Li, Tianyu Wang, Hirofumi Tanaka, Jeffrey D. Browning
Metabolic Brain Disease.2025;[Epub] CrossRef FGF21 reverses MASH through coordinated actions on the CNS and liver
Jesse P. Rose, Donald A. Morgan, Andrew I. Sullivan, Xiaorong Fu, Melissa Inigo-Vollmer, Shawn C. Burgess, David K. Meyerholz, Kamal Rahmouni, Matthew J. Potthoff
Cell Metabolism.2025; 37(7): 1515. CrossRef Liver cirrhosis in metabolic dysfunction-associated steatohepatitis
Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah
Gastroenterology Report.2025;[Epub] CrossRef From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease—A systematic review
Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, Stefan‐Lucian Popa, Teodora Surdea‐Blaga, Dan L. Dumitrascu
European Journal of Clinical Investigation.2025;[Epub] CrossRef Developing and validating a predictive model for all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease
Fan Zhang, Longgen Liu, Wenjian Li
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
Zhifa Ge, Qingwei Wu, Chengyu Lv, Qifeng He
Immunology.2025;[Epub] CrossRef Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
Biomedicines.2025; 13(5): 1260. CrossRef Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
Yusuf Yilmaz, Caglayan Keklikkiran, Andrei Racila, Maria Stepanova, Zobair M. Younossi
Clinical and Translational Gastroenterology.2025; 16(6): e00844. CrossRef Impact of Metabolic Dysfunction–associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure
Bhavik Bansal, Fannie Lajeunesse-Trempe, Neil Keshvani, Carl J. Lavie, Ambarish Pandey
Canadian Journal of Cardiology.2025;[Epub] CrossRef Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis
舒惟 梁
Advances in Clinical Medicine.2025; 15(05): 2063. CrossRef Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults
James M. Paik, Kathryn Hobbs, Amolika Gupta, Rand Jamal Alkalbani, Manuel Alexander Reyes, Zobair M. Younossi
Journal of Clinical Gastroenterology.2025;[Epub] CrossRef Association between weight fluctuation and the risk of metabolic dysfunction-associated steatotic liver disease
Jin-Ping Wang, Jia-Yang Wang, Pei-Qi Sun, Xue-Wei Wang, Ze-Ting Yuan, Qin Cao, Shu-Ming Pan, Yuan-Ye Jiang
World Journal of Hepatology.2025;[Epub] CrossRef Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease
Jonathan Mertens, Jonas Weyler, Eveline Dirinck, Luisa Vonghia, Wilhelmus J. Kwanten, Luc F. Van Gaal, Benedicte Y. De Winter, Sven Francque, Christophe De Block
Cardiovascular Diabetology.2025;[Epub] CrossRef The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study
Arjuna P De Silva, Krishanni Prabagar, Anuradha S Wickramasinghage, Aruni A Wanniarachchi, Dileepa S Ediriweera, Madunil A Niriella, Hithanadura J De Silva
Cureus.2025;[Epub] CrossRef GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)
Laura Pagès, Aina Martí-Carretero, Diego Rojo, Clara Sabiote, Farnaz Faninam, Sophia C. Parks, María Martínez-Gómez, M Serra Cusidó, Neda Akhlaghi, Sergio Muñoz-Martínez, Alba Jiménez-Masip, Juan M. Pericàs
Current Hepatology Reports.2025;[Epub] CrossRef Challenges in Applying MASLD Risk Algorithms in Pregnancy: A Call for Adaptation and Inclusion
Nina Rodriguez, Cecilia Katzenstein, Marcia Lange, Jeanette Rios, Tatyana Kushner, Rachel Meislin, Emma Rosenbluth, Carin Carroll, Theresa Worthington, Shaelyn O’Hara, Joanne Stone, Sonam Rosberger, Keith Sigel, Rhoda Sperling, Norah A. Terrault
Journal of Hepatology.2025;[Epub] CrossRef Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A. Brenner, Frank Tacke
Cellular & Molecular Immunology.2025;[Epub] CrossRef Association between trans-palmitoleic acid and metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma: NHANES 1999–2018
Qirui Li, Luqi Zhan, Qian Li, Shuai Zhu, Shuaihui Liu, He Jiang, Jinlin Cheng, Lanjuan Li
Frontiers in Nutrition.2025;[Epub] CrossRef To sleeve or not to sleeve: Validation of liver transplantation with sleeve gastrectomy
Linda W. Moore, Elizabeth W. Brombosz, R. Mark Ghobrial
Journal of Hepatology.2025;[Epub] CrossRef Redefining Diagnosis and Management in Hepatology with Multiparametric Ultrasound
Yolande Chalmers
EMJ Hepatology.2025; : 66. CrossRef Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual
Current Obesity Reports.2025;[Epub] CrossRef Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts
Nutrients.2025; 17(13): 2189. CrossRef Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population
Wei Li, Lina Jiang, Meiling Li, Chen Lin, Li Zhu, Bokang Zhao, Yisi Liu, Yan Li, Yiyun Jiang, Shuhong Liu, Ping Liang, Junqi Niu, Jingmin Zhao
Gastroenterology Report.2025;[Epub] CrossRef Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay
Eleni Myrto Trifylli, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch
International Journal of Molecular Sciences.2025; 26(13): 6333. CrossRef Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses
Ninglin Xia, Jiwei Wang, Qian Lu, Xue Fan, Zhenzhou Jiang, Qinwei Yu
Clinical Nutrition ESPEN.2025; 68: 679. CrossRef Time trends and health inequalities of cirrhosis caused by metabolic Dysfunction-associated steatotic liver disease from 1990 to 2021: A global burden of disease study
Min Wu, Yifeng Li, Dong Liu, Weinong Wen, Yan Min, Qiang Su, Zhenxiang An, Xiaofang Yang
Journal of Endocrinological Investigation.2025;[Epub] CrossRef Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Philip N. Newsome, Rohit Loomba
Journal of Clinical Investigation.2025;[Epub] CrossRef Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease
Alina M. Allen, W. Ray Kim, Patrizia Carrieri, Rachel Canning, Fang-Shu Ou, Joanne Benson, Jessica L. Olson, Sudhakar K. Venkatesh, Jiahui Li, Meng Yin, Maysa Eslami, Richard L. Ehman, Jennifer Hunter Berg, Jeffrey V. Lazarus
Hepatology.2025;[Epub] CrossRef High Prevalence of Fatty Liver in Bangladeshi Adolescents and Young Adults with Type 2 Diabetes: Key Predictors and Screening Recommendations
Kishore Shil, Mashfiqul Hasan, Nusrat Sultana, Sayad Salam, Syeda Mostafa, Muhammad Hasanat
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 2019. CrossRef Adipose Tissue Dysfunction and Hepatic Steatosis in New-Onset Diabetes
Emilia Rusu, Mariana Jinga, Raluca Cursaru, Georgiana Enache, Adrian Costache, Ioana Verde, Andra Nica, Anca Alionescu, Florin Rusu, Gabriela Radulian
Diabetology.2025; 6(7): 70. CrossRef Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi
Nutrients.2025; 17(13): 2211. CrossRef Altered HDL Phospholipid and Fatty Acid Profile in MASLD: A Possible Explanation for the Increased CVD Risk
Sofia Kartsoli, Christina E. Kostara, Athanasios Papathanasiou, Vasilis Tsimihodimos, Eleni T. Bairaktari, Dimitrios K. Christodoulou
International Journal of Molecular Sciences.2025; 26(13): 6148. CrossRef Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis
Qing Zhou, Jisu Xue, Lu Hao
BMC Gastroenterology.2025;[Epub] CrossRef Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018
Yanshan Yi, Li Yang
Frontiers in Nutrition.2025;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights
Wan-Qi Yang, Ling-Ling Xue, Jing-Lin Wang
World Journal of Gastroenterology.2025;[Epub] CrossRef Kidney function mediates the association of per- and poly-fluoroalkyl substances (PFAS) and heavy metals with hepatic fibrosis risk
Zhengqi Wei, Jincheng Liu, Na Wang, Keke Wei
Environmental Research.2024; 263: 120092. CrossRef Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis
Fahad Lakhdhir, Agha Syed Muhammad, Ahmed Nasir Qureshi, Imran A Shaikh, Imran Joher, Jawaria Majeed, Javaria Khan
Cureus.2024;[Epub] CrossRef Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clinical and Molecular Hepatology.2024; 30(4): 982. CrossRef Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification
Han Ah Lee
The Korean Journal of Internal Medicine.2024; 39(6): 869. CrossRef AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease
Sheza Malik, Rishi Das, Thanita Thongtan, Kathryn Thompson, Nader Dbouk
Journal of Clinical Medicine.2024; 13(24): 7833. CrossRef
|